1. Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemia
    Zhengwei Wu et al, 2023, Cancer Medicine CrossRef
  2. Siglec-6 CAR T: magic bullet for a moving target
    Sara Ghorashian et al, 2021, Blood CrossRef
  3. Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands
    Ali N. Kamali et al, 2023, Therapeutic Advances in Vaccines and Immunotherapy CrossRef
  4. The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways
    Maryam Bakhtiyari et al, 2023, Cell Communication and Signaling CrossRef
  5. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes
    Amany M. Kamal et al, 2021, Clinical Biochemistry CrossRef
  6. TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes
    Jian Hong et al, 2022, Frontiers in Oncology CrossRef
  7. Immunotherapy in leukaemia
    Xingmei Mu et al, 2023, Acta Biochimica et Biophysica Sinica CrossRef
  8. A T-cell receptor as a promising immunotherapeutic target in acute myeloid leukemia: expression of T cell immunoglobulin and mucin-containing-3 on bone marrow hematopoietic cells
    Heba M Atif et al, 2024, The Egyptian Journal of Haematology CrossRef
  9. The prospective prognostic value of the immune checkpoint BTLA expression in adult acute myeloid leukemia patients
    Sara M. Radwan et al, 2021, Egyptian Journal of Medical Human Genetics CrossRef
  10. NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia
    Kateřina Kuželová et al, 2022, OncoImmunology CrossRef
  11. The role of circular RNA plasmacytoma variant translocation 1 as a biomarker for prognostication of acute myeloid leukemia
    Tao Chen et al, 2021, Hematology CrossRef
  12. Activated Tim-3/Galectin-9 participated in the development of multiple myeloma by negatively regulating CD4 T cells
    Rui Zhang et al, 2024, Hematology CrossRef
  13. Catch me if you can: how AML and its niche escape immunotherapy
    Sarah Tettamanti et al, 2022, Leukemia CrossRef